{"success":true,"data":{"pressRelease":{"id":"162009","rtpr_id":"nBw14BMXXa-20261006","ticker":"SLP","exchange":"NASDAQ","all_tickers":["SLP"],"title":"Simulations Plus Announces Completion of Acquisition by Altaris","author":"Business Wire","published_at":"2026-10-06T13:15:00.132Z","article_body":"Simulations Plus Announces Completion of Acquisition by Altaris\n\nSimulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the\n“Company”), a global leader in model-informed and AI-accelerated drug\ndevelopment that advances biopharma innovation, today announced the completion\nof its acquisition by affiliates of Altaris, LLC (\"Altaris\"), an investment\nfirm focused exclusively on the healthcare industry.\n\nThe transaction was originally announced on June 16, 2026. At the effective\ntime of the merger each Simulations Plus shareholder received $18.50 in cash\nper share. As a result of the completion of the transaction, Simulations Plus\nhas become a privately held company, and its common stock will no longer trade\non the Nasdaq Global Select Market.\n\nAs previously announced, in connection with closing, Simulations Plus is being\ncombined with Chemical Computing Group (\"CCG\"), an Altaris portfolio company\nand leading provider of molecular modeling and drug discovery software.\nTogether, the organizations will create a broader platform spanning drug\ndiscovery, modeling, simulation, and development, enhancing their ability to\nserve customers across the pharmaceutical research and development lifecycle.\nWithin the combined business, Simulations Plus will continue to operate under\nits own name and brand.\n\n\"Today marks an exciting new chapter for Simulations Plus,\" said Shawn\nO'Connor, Chief Executive Officer of Simulations Plus. \"Our mission has always\nbeen to help our customers accelerate the discovery, development, and\ncommercialization of innovative therapies through advanced modeling,\nsimulation, and AI-driven technologies. By joining CCG, we believe we are well\npositioned to accelerate investment in innovation, expand our capabilities,\nand expand the solution we provide to customers across the biopharmaceutical\necosystem. We want to thank our employees, customers, partners, and\nshareholders for their support throughout our journey as a public company.\"\n\n\"We are delighted to welcome the Simulations Plus team to CCG,\" said Paul\nLabute, Chief Executive Officer at CCG. \"Simulations Plus has established\nitself as a trusted leader in biosimulation and model-informed drug\ndevelopment, supported by its science, differentiated technology, and deep\ncustomer relationships. We look forward to partnering with the company's\ntalented team to support continued growth and innovation while advancing\nsolutions that help improve the efficiency and success of drug development.\"\n\nThe combined organization will leverage the complementary technologies,\nscientific expertise, and customer relationships of both companies to\naccelerate innovation and provide an expanded suite of software and services\nsupporting biopharmaceutical research and development.\n\nAbout Simulations Plus, Inc.\n\nSimulations Plus is a global leader in model-informed and AI-accelerated drug\ndevelopment. We create value for our clients by accelerating the discovery,\ndevelopment, and commercialization of pharmaceuticals and other products\nthrough innovative science-based software and consulting solutions. For more\ninformation, visit www.simulations-plus.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.simulations-plus.com&esheet=54616477&newsitemid=20261006258966&lan=en-US&anchor=www.simulations-plus.com&index=1&md5=e8b0aec33b6a15b0cdef6c8db2bdaac2)\n.\n\nAbout Altaris\n\nAltaris is an investment firm with an exclusive focus on acquiring and\nbuilding companies in the healthcare industry. Since its inception in 2003,\nAltaris has invested in more than 50 companies across a range of healthcare\nsubsectors, with a consistent goal of delivering value to the healthcare\nsystem and generating attractive financial returns for investors. Altaris is\nheadquartered in New York City and manages $10 billion of equity capital. For\nmore information, please visit www.altariscap.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.altariscap.com&esheet=54616477&newsitemid=20261006258966&lan=en-US&anchor=www.altariscap.com&index=2&md5=e2fe0c70da12dcbd2d4bd0f2d7c42c04)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261006258966/en/\n(https://www.businesswire.com/news/home/20261006258966/en/)\n\nMedia Contact:\nLisa Fortuna\nFinancial Profiles\n310-622-8251\nslp@finprofiles.com (mailto:slp@finprofiles.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw14BMXXa-20261006","title":"Simulations Plus Announces Completion of Acquisition by Altaris","author":"Business Wire","ticker":"SLP","created":"2026-10-06T13:15:00.132Z","tickers":["SLP"],"exchange":"NASDAQ","article_body":"Simulations Plus Announces Completion of Acquisition by Altaris\n\nSimulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the\n“Company”), a global leader in model-informed and AI-accelerated drug\ndevelopment that advances biopharma innovation, today announced the completion\nof its acquisition by affiliates of Altaris, LLC (\"Altaris\"), an investment\nfirm focused exclusively on the healthcare industry.\n\nThe transaction was originally announced on June 16, 2026. At the effective\ntime of the merger each Simulations Plus shareholder received $18.50 in cash\nper share. As a result of the completion of the transaction, Simulations Plus\nhas become a privately held company, and its common stock will no longer trade\non the Nasdaq Global Select Market.\n\nAs previously announced, in connection with closing, Simulations Plus is being\ncombined with Chemical Computing Group (\"CCG\"), an Altaris portfolio company\nand leading provider of molecular modeling and drug discovery software.\nTogether, the organizations will create a broader platform spanning drug\ndiscovery, modeling, simulation, and development, enhancing their ability to\nserve customers across the pharmaceutical research and development lifecycle.\nWithin the combined business, Simulations Plus will continue to operate under\nits own name and brand.\n\n\"Today marks an exciting new chapter for Simulations Plus,\" said Shawn\nO'Connor, Chief Executive Officer of Simulations Plus. \"Our mission has always\nbeen to help our customers accelerate the discovery, development, and\ncommercialization of innovative therapies through advanced modeling,\nsimulation, and AI-driven technologies. By joining CCG, we believe we are well\npositioned to accelerate investment in innovation, expand our capabilities,\nand expand the solution we provide to customers across the biopharmaceutical\necosystem. We want to thank our employees, customers, partners, and\nshareholders for their support throughout our journey as a public company.\"\n\n\"We are delighted to welcome the Simulations Plus team to CCG,\" said Paul\nLabute, Chief Executive Officer at CCG. \"Simulations Plus has established\nitself as a trusted leader in biosimulation and model-informed drug\ndevelopment, supported by its science, differentiated technology, and deep\ncustomer relationships. We look forward to partnering with the company's\ntalented team to support continued growth and innovation while advancing\nsolutions that help improve the efficiency and success of drug development.\"\n\nThe combined organization will leverage the complementary technologies,\nscientific expertise, and customer relationships of both companies to\naccelerate innovation and provide an expanded suite of software and services\nsupporting biopharmaceutical research and development.\n\nAbout Simulations Plus, Inc.\n\nSimulations Plus is a global leader in model-informed and AI-accelerated drug\ndevelopment. We create value for our clients by accelerating the discovery,\ndevelopment, and commercialization of pharmaceuticals and other products\nthrough innovative science-based software and consulting solutions. For more\ninformation, visit www.simulations-plus.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.simulations-plus.com&esheet=54616477&newsitemid=20261006258966&lan=en-US&anchor=www.simulations-plus.com&index=1&md5=e8b0aec33b6a15b0cdef6c8db2bdaac2)\n.\n\nAbout Altaris\n\nAltaris is an investment firm with an exclusive focus on acquiring and\nbuilding companies in the healthcare industry. Since its inception in 2003,\nAltaris has invested in more than 50 companies across a range of healthcare\nsubsectors, with a consistent goal of delivering value to the healthcare\nsystem and generating attractive financial returns for investors. Altaris is\nheadquartered in New York City and manages $10 billion of equity capital. For\nmore information, please visit www.altariscap.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.altariscap.com&esheet=54616477&newsitemid=20261006258966&lan=en-US&anchor=www.altariscap.com&index=2&md5=e2fe0c70da12dcbd2d4bd0f2d7c42c04)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261006258966/en/\n(https://www.businesswire.com/news/home/20261006258966/en/)\n\nMedia Contact:\nLisa Fortuna\nFinancial Profiles\n310-622-8251\nslp@finprofiles.com (mailto:slp@finprofiles.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-06T13:15:00.20117344Z","server_sent_at_ms":1791292500201},"received_at":"2026-10-06T13:15:00.252Z","source_url":"https://www.businesswire.com/news/home/20261006258966/en/"},"analysis":{"id":"150518","press_release_id":"162009","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["SLP common stock will no longer trade on Nasdaq -- ticker becomes non-actionable for traders"],"eventType":"m_and_a","narrative":"Simulations Plus has completed its acquisition by affiliates of Altaris, LLC, with each SLP shareholder receiving $18.50 in cash per share.\n\nThe company is now privately held and its common stock will no longer trade on the Nasdaq Global Select Market; the deal was originally announced June 16, 2026.\n\nAt closing, Simulations Plus is being combined with Chemical Computing Group, an Altaris portfolio company, creating a broader drug discovery and simulation platform while the Simulations Plus brand continues to operate.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"SLP take-private closes at $18.50/share cash; shareholders cashed out and the ticker delists from Nasdaq."},"keyFigures":{"dealValueUsd":"$18.50 per share in cash","customDimensions":{"acquirerEquityCapital":"$10 billion","originalAnnouncementDate":"June 16, 2026","perShareMergerConsideration":18.5}},"quotedText":"Today marks an exciting new chapter for Simulations Plus","namedEntities":{"people":[{"name":"Shawn O'Connor","role":"CEO of Simulations Plus"},{"name":"Paul Labute","role":"CEO of Chemical Computing Group"},{"name":"Lisa Fortuna","role":"media contact, Financial Profiles"}],"products":[],"companies":[{"name":"Simulations Plus, Inc.","ticker":"SLP","relationship":"filer / target"},{"name":"Altaris, LLC","relationship":"acquirer"},{"name":"Chemical Computing Group (CCG)","relationship":"Altaris portfolio company / merger partner"},{"name":"Financial Profiles","relationship":"media relations"}],"dollarAmounts":[{"amount":"$18.50","context":"cash per share paid to Simulations Plus shareholders"},{"amount":"$10 billion","context":"equity capital managed by Altaris"}]},"materialImpact":{"score":4,"reasoning":"Completion of the take-private acquisition of the filer by Altaris affiliates at $18.50 per share; SLP is delisting from Nasdaq and will combine with Chemical Computing Group. This is the closing of a previously announced M&A deal, so it is material but no longer a surprise catalyst."},"tickerRelevance":{"others":[],"primary":"SLP"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"novelty":"closing of previously announced deal, limited surprise","tickerTier":"small-cap","eventGravity":"M&A closing / take-private and delisting","marketCapAdjustment":"mid-small cap healthcare software"}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"neutral","material_impact_score":4,"narrative":"Simulations Plus has completed its acquisition by affiliates of Altaris, LLC, with each SLP shareholder receiving $18.50 in cash per share.\n\nThe company is now privately held and its common stock will no longer trade on the Nasdaq Global Select Market; the deal was originally announced June 16, 2026.\n\nAt closing, Simulations Plus is being combined with Chemical Computing Group, an Altaris portfolio company, creating a broader drug discovery and simulation platform while the Simulations Plus brand continues to operate.","key_figures":{"dealValueUsd":"$18.50 per share in cash","customDimensions":{"acquirerEquityCapital":"$10 billion","originalAnnouncementDate":"June 16, 2026","perShareMergerConsideration":18.5}},"named_entities":{"people":[{"name":"Shawn O'Connor","role":"CEO of Simulations Plus"},{"name":"Paul Labute","role":"CEO of Chemical Computing Group"},{"name":"Lisa Fortuna","role":"media contact, Financial Profiles"}],"products":[],"companies":[{"name":"Simulations Plus, Inc.","ticker":"SLP","relationship":"filer / target"},{"name":"Altaris, LLC","relationship":"acquirer"},{"name":"Chemical Computing Group (CCG)","relationship":"Altaris portfolio company / merger partner"},{"name":"Financial Profiles","relationship":"media relations"}],"dollarAmounts":[{"amount":"$18.50","context":"cash per share paid to Simulations Plus shareholders"},{"amount":"$10 billion","context":"equity capital managed by Altaris"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T13:15:06.258Z","global_importance":45,"audience_relevance":35,"importance_components":{"novelty":"closing of previously announced deal, limited surprise","tickerTier":"small-cap","eventGravity":"M&A closing / take-private and delisting","marketCapAdjustment":"mid-small cap healthcare software"}},"durationMs":5992,"modelName":"glm-5.3-flashx"}}